Pluristem Therapeutics (PSTI) PT Cut to $3 at Maxim Group; 'Buy' Maintained
Tweet Send to a Friend
Maxim Group analyst Jason Kolbert lowered his price target on Pluristem Therapeutics (NASDAQ: PSTI) to $3.00 (from $8.00) but maintained ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
